Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

  1. Barcenas, C.H.
  2. Hurvitz, S.A.
  3. Di Palma, J.A.
  4. Bose, R.
  5. Chien, A.J.
  6. Iannotti, N.
  7. Marx, G.
  8. Brufsky, A.
  9. Litvak, A.
  10. Ibrahim, E.
  11. Alvarez, R.H.
  12. Ruiz-Borrego, M.
  13. Chan, N.
  14. Manalo, Y.
  15. Kellum, A.
  16. Trudeau, M.
  17. Thirlwell, M.
  18. Garcia Saenz, J.
  19. Hunt, D.
  20. Bryce, R.
  21. McCulloch, L.
  22. Rugo, H.S.
  23. Tripathy, D.
  24. Chan, A.
  25. Carcas, L.
  26. Castrellon, A.
  27. Chan, D.
  28. Cheong, K.
  29. Choi, B.
  30. Coleman, M.
  31. Conlin, A.
  32. Dichmann, R.
  33. Ellison, D.
  34. Erickson, N.
  35. Gore, I.
  36. Hansen, V.
  37. Huang, D.
  38. Hufnagel, D.
  39. Kass, F.
  40. Kendall, S.D.
  41. Kozloff, M.
  42. Lawler, W.
  43. Nahum, K.D.
  44. Pistilli, B.
  45. Reyes, E.
  46. Seeger, J.
  47. Somer, R.
  48. Chiu, E.T.
  49. Thomas, G.
  50. Tkaczuk, K.
  51. Vaziri, I.
  52. Wade, J.
  53. Wilkinson, M.
  54. Show all authors +
Journal:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Year of publication: 2020

Volume: 31

Issue: 9

Pages: 1223-1230

Type: Article

DOI: 10.1016/J.ANNONC.2020.05.012 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus